P K Sonsalla
Overview
Explore the profile of P K Sonsalla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeevalk G, Manzino L, Sonsalla P, Bernard L
Exp Neurol
. 2006 Oct;
203(2):512-20.
PMID: 17049515
Parkinson's disease (PD) is associated with loss of total glutathione (GSH) which may contribute to progressive cell death. Peripheral GSH administration has been used clinically with reported benefits. Despite this,...
2.
Yazdani U, German D, Liang C, Manzino L, Sonsalla P, Zeevalk G
Exp Neurol
. 2006 Mar;
200(1):172-83.
PMID: 16546169
Mitochondrial dysfunction is observed in sporadic Parkinson's disease (PD) and may contribute to progressive neurodegeneration. While acute models of mitochondrial dysfunction have been used for many years to investigate PD,...
3.
Gluck M, Moy L, Jayatilleke E, Hogan K, Manzino L, Sonsalla P
J Neurochem
. 2001 Oct;
79(1):152-60.
PMID: 11595767
The neurotoxic actions of methamphetamine (METH) may be mediated in part by reactive oxygen species (ROS). Methamphetamine administration leads to increases in ROS formation and lipid peroxidation in rodent brain;...
4.
Zeevalk G, Bernard L, Manzino L, Sonsalla P
J Pharmacol Exp Ther
. 2001 Aug;
298(3):925-33.
PMID: 11504786
Disturbance in phosphorylation/dephosphorylation can trigger apoptosis. Little is known as to its effects on mesencephalic dopamine neurons, the major neurons lost in Parkinson's disease. In this study, okadaic acid (OKA),...
5.
Staal R, Yang J, Hait W, Sonsalla P
Brain Res
. 2001 Aug;
910(1-2):116-25.
PMID: 11489261
The vesicular monoamine transporter 2 (VMAT2) has sequence homology with bacterial multidrug transporters which in turn share homology with mammalian P-glycoprotein (P-GP). Both VMAT2 and P-GP can detoxify cells. 1-Methyl-4-phenylpyridinium...
6.
Chen J, Xu K, Petzer J, Staal R, Xu Y, Beilstein M, et al.
J Neurosci
. 2001 May;
21(10):RC143.
PMID: 11319241
Recent epidemiological studies have established an association between the common consumption of coffee or other caffeinated beverages and a reduced risk of developing Parkinson's disease (PD). To explore the possibility...
7.
German D, Liang C, Manaye K, Lane K, Sonsalla P
Neuroscience
. 2000 Dec;
101(4):1063-9.
PMID: 11113355
The vesicular monoamine transporter in the brain can sequester the neurotoxin 1-methyl-4-phenylpyridinium into synaptic vesicles and protect catecholamine-containing neurons from degeneration. Mouse nigrostriatal dopaminergic neurons, and to a lesser extent...
8.
Hogan K, Staal R, Sonsalla P
J Neurochem
. 2000 May;
74(5):2217-20.
PMID: 10800969
[3H]Dihydrotetrabenazine ([3H]DTBZ), a specific ligand for the vesicular monoamine transporter (VMAT2), has been used to characterize the integrity of monoaminergic nerve terminals in experimental animals and humans. The purpose of...
9.
Staal R, Sonsalla P
J Pharmacol Exp Ther
. 2000 Apr;
293(2):336-42.
PMID: 10773000
Dopamine neurons from various animal species differ in sensitivity to the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 1-methyl-4-phenylpyridinium (MPP(+)). Compared with striatal vesicles isolated from mice, those from rats have a...
10.
Staal R, Hogan K, Liang C, German D, Sonsalla P
J Pharmacol Exp Ther
. 2000 Apr;
293(2):329-35.
PMID: 10772999
Significant differences exist in the sensitivity of mice and rats to the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) that cannot be explained by differences in exposure to or uptake of 1-methyl-4-phenylpyridinium (MPP(+))...